Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Clin Infect Dis
; 48(10): 1471-4, 2009 May 15.
Article
em En
| MEDLINE
| ID: mdl-19368504
ABSTRACT
Rifamycin-resistant Mycobacterium tuberculosis infection (i.e., by a strain of M. tuberculosis that is only resistant to rifamycins) occurs disproportionately among patients infected with the human immunodeficiency virus (HIV) who have a low CD4 cell count. We observed 3 genetically confirmed cases of relapse with rifamycin-resistant M. tuberculosis infection following concurrent treatment with rifabutin (dosage, 150 mg every other day) and a ritonavir-boosted HIV protease inhibitor during a prior episode of drug-susceptible tuberculosis. Higher doses of rifabutin and a ritonavir-boosted HIV protease inhibitor as treatment for tuberculosis should be studied further.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Infecções por HIV
/
Rifabutina
/
Terapia Antirretroviral de Alta Atividade
/
Farmacorresistência Bacteriana
/
Mycobacterium tuberculosis
/
Antituberculosos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article